Bris­tol My­er­s' block­buster-to-be Re­blozyl scores a PhI­II win

Bris­tol My­ers Squibb un­veiled a sur­prise vic­to­ry on Mon­day for its po­ten­tial $4 bil­lion-per-year drug Re­blozyl, with the bio­phar­ma an­nounc­ing that it hit a pri­ma­ry end­point for a Phase III tri­al.

The pos­i­tive re­sult, de­fined as a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment” in red blood cell trans­fu­sion in­de­pen­dence (RBC-TI), or how long a pa­tient with ane­mia goes with­out a trans­fu­sion, with in­creas­ing lev­els of he­mo­glo­bin in­creas­ing in pa­tients who re­quire red blood cell trans­fu­sions, fol­lows FDA push­back on a third ap­proval in March.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN